First‑Line Management of Abnormal Prolonged Menstrual Bleeding

NSAID First‑Line Therapy

• The Centers for Disease Control and Prevention/World Health Organization (CDC/WHO) recommend a 5–7‑day course of non‑steroidal anti‑inflammatory drugs (NSAIDs) as the initial treatment for abnormal prolonged menstrual bleeding, irrespective of contraceptive use or underlying structural pathology. Strong, consistent evidence across multiple studies supports this recommendation. [1][2]3
• Mefenamic acid 500 mg three times daily for 5 days significantly reduces bleeding within 7 days compared with placebo. Strong evidence from randomized trials. [4][5]
• Celecoxib 200 mg once daily for 5 days is an acceptable alternative NSAID regimen. Strong evidence from comparative studies. [4][5]
• Other NSAIDs—including ibuprofen, indomethacin, and diclofenac—have demonstrated efficacy in reducing menstrual blood loss. Strong evidence from multiple trials. [6][7]
• NSAIDs achieve bleeding reduction by inhibiting prostaglandin synthesis, thereby decreasing endometrial bleeding. Mechanistic evidence supporting clinical effect. [6][7]
• The efficacy of NSAIDs is consistent across all contraceptive methods (copper IUD, levonorgestrel IUD, implants, depot medroxyprogesterone acetate) and in non‑contraceptive‑related bleeding. Strong, broad‑based evidence. [1][2][3][8]

Hormonal Second‑Line Therapy (If NSAIDs Fail or Bleeding Is Severe)

• When NSAIDs are ineffective or the patient desires additional control, a 10–20‑day course of hormonal therapy during bleeding episodes is recommended. Moderate evidence from CDC/WHO guidance. [1][4]5
• Low‑dose combined oral contraceptives (COCs) administered for 10–20 days effectively reduce bleeding. Moderate evidence. [1][4]5
• Estrogen therapy given for 10–20 days is an alternative hormonal option with comparable efficacy. Moderate evidence. [1][4]5

Evidence Base and Strength of Recommendations

• The treatment algorithm is derived from the CDC/WHO Selected Practice Recommendations for Contraceptive Use (2013), which provide expert consensus and consistent treatment pathways across clinical scenarios. [1][2][3][8]

Special Population: Women Using Contraception

• The same NSAID‑first, hormonal‑second algorithm applies regardless of the contraceptive method being used. Strong evidence of uniform applicability. [1][2][3][8]
• Patients should be reassured that irregular bleeding associated with contraceptive use is generally benign and not harmful. Moderate evidence supporting reassurance. [1][4]9

Escalation and Diagnostic Work‑up

• If bleeding persists despite optimal medical therapy or is unacceptable to the patient, clinicians should counsel on alternative contraceptive options or refer for further evaluation. Strong evidence for escalation pathway. [1][2][3][6]
• Recommended diagnostic investigations include:
  
  • Transvaginal ultrasound, saline‑infusion sonohysterography, or hysteroscopy to identify structural lesions (e.g., polyps, fibroids, adenomyosis). Evidence‑based imaging recommendations. 10
  • Serum thyroid‑stimulating hormone and prolactin measurements to assess for ovulatory dysfunction. Evidence‑based endocrine work‑up. 11
  • Endometrial biopsy for individuals aged >45 years or those with risk factors for endometrial cancer. Evidence‑based pathology recommendation. 11

Common Pitfalls to Avoid

• Do not skip NSAIDs and proceed directly to hormonal therapy; NSAIDs are effective, well‑tolerated, and appropriate for most patients. Strong evidence supporting this sequencing. [1][2]3
• Aspirin should not be used for menstrual bleeding reduction, as it does not decrease blood loss and may exacerbate bleeding. Evidence demonstrates lack of benefit and potential harm. [6][5]7

Management of Heavy Vaginal Bleeding

Initial Assessment and Stabilization

• Assess hemodynamic status and obtain hemoglobin/hematocrit to gauge anemia severity; intervene with transfusion or iron infusion when indicated【@5】.
• Rule out pregnancy in all women of reproductive age using urine or serum β‑hCG【@4】.
• Review current medications, especially anticoagulants and antiepileptic drugs, for potential contribution to bleeding【@6】.
• Identify contraceptive use as a common cause of irregular bleeding【@7】.

First‑Line Medical Therapy

• NSAIDs for 5–7 days are recommended as the initial treatment for heavy vaginal bleeding regardless of contraceptive method or underlying cause【@7】.
• Mefenamic acid 500 mg three times daily for 5 days significantly reduces bleeding within 7 days compared with placebo【@7】.
• Celecoxib 200 mg once daily for 5 days is an acceptable alternative NSAID【@7】.

Second‑Line Hormonal Therapy

• If NSAIDs fail or bleeding is severe, prescribe low‑dose combined oral contraceptives (COCs) or estrogen therapy for 10–20 days【@7】.
• Confirm medical eligibility before initiating hormonal therapy (e.g., no history of venous thromboembolism, age > 35 years with smoking, migraine with aura)【@7】.

Evaluation for Underlying Causes

• Investigate drug interactions, particularly with anticoagulants and antiepileptic agents【@7】.
• Screen for sexually transmitted infections and pregnancy‑related complications when clinically indicated【@7】.
• Assess for structural uterine pathology (polyps, fibroids, adenomyosis) using transvaginal ultrasound, saline‑infusion sonohysterography, or hysteroscopy【@8】.
• Consider endometrial hyperplasia or malignancy, especially in perimenopausal women【@5】.
• Order thyroid‑stimulating hormone and prolactin levels to evaluate ovulatory dysfunction【@8】.
• Perform endometrial biopsy in patients > 45 years or with risk factors for endometrial cancer【@8】.

Special Populations

Women on Anticoagulation

• Management should be multidisciplinary, involving gynecology and hematology/thrombosis specialists【@6】.
• Discuss possible anticoagulant switching or dose reduction with the prescribing specialist【@6】.
• Tranexamic acid is especially useful as an antifibrinolytic adjunct【@6】.
• Combined hormonal contraceptives can be safely prescribed in selected anticoagulated patients by experienced clinicians【@6】.

Contraceptive‑Related Bleeding

• Begin with NSAIDs for 5–7 days; if ineffective, add COCs or short‑course estrogen (10–20 days)【@7】.
• Reassure patients that most irregular bleeding associated with contraceptives is not harmful【@7】.
• If bleeding remains unacceptable, counsel on alternative contraceptive options【@7】.

Surgical Management (when medical therapy fails or is contraindicated)

• Endometrial ablation【@8】.
• Hysterectomy【@8】.
• Diagnostic and therapeutic hysteroscopy for focal lesions【@8】.

Common Pitfalls to Avoid

• Never assume pregnancy is impossible; always test before starting hormonal therapy【@4】.
• Do not categorically label all hormonal methods contraindicated in anticoagulated patients; individualized assessment is required【@6】.
• Promptly provide iron supplementation or transfusion in severely anemic patients【@5】.